A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Howard S Hochster
Study ID
NCT04829383
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.

Key Dates

Start date
Mar 22, 2021
Status verified
Apr 2025
Primary completion
Oct 31, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study Treatment
    Atezolizumab 1,200 mg IV and bevacizumab 15 mg/kg IV every 3 weeks (on day 1 of each 21-day cycle). Treatment will continue until disease progression or development of unacceptable toxicity.

Primary Outcome Measure

Frequency and severity of toxicities [ Time Frame: 1 year ]

Locations (7)

FacilityCityStateZIPSite coordinators
University of Illinois Cancer CenterChicagoIllinois60612-
Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolisIndiana46202-
University of Nebraska Medical CenterOmahaNebraska68198-
Rutgers Cancer Institute of New JerseyNew BrunswickNew Jersey08903-
New York University Clinical Cancer CenterNew YorkNew York10016-
DHR Health Institute for Research and DevelopmentEdinburgTexas785329-
Univeristy of WisconsinMadisonWisconsin53705-

Find similar trials in Chicago, IL

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
University of Illinois Cancer Center· Chicago, ILIndiana University Melvin and Bren Simon Comprehensive Cancer Center· Indianapolis, INUniversity of Nebraska Medical Center· Omaha, NERutgers Cancer Institute of New Jersey· New Brunswick, NJNew York University Clinical Cancer Center· New York, NYDHR Health Institute for Research and Development· Edinburg, TX

Related Studies